Ajouter à une liste

Instrument Inactif

Communiqués Endocare, Inc.

Actions

US29264P2039

Equipement et technologie médicale avancés

Cours en clôture Nasdaq
- ^USD	-

Communiqués

30/11/-1	ENDOCARE : to Present at Oppenheimer 19th Annual Healthcare Conference	PR
30/11/-1	ENDOCARE : and Former CEO Paul W. Mikus Agree to Terminate Indemnification Agreement	PR
30/11/-1	ENDOCARE : Terrence A. Noonan Named Endocare Interim President and Interim Chief Executive Officer	PR
30/11/-1	ENDOCARE : to Present at Third Annual JMP Securities Healthcare Focus Conference	PR
30/11/-1	ENDOCARE : and Former CFO Agree to Terminate Indemnification Agreement	PR
30/11/-1	ENDOCARE : to Present at 28th Annual Canaccord Adams Global Growth Conference	PR
30/11/-1	ENDOCARE : Reports Financial Results for Second Quarter 2008	PR
30/11/-1	ENDOCARE : Joins Russell Microcap Index	PR
30/11/-1	ENDOCARE : Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer	PR
30/11/-1	Endocare : Endocare to Present at Seventh Annual JMP Securities Research Conference	PR
30/11/-1	Endocare : Endocare Reports 2008 First Quarter Financial Results	PR
30/11/-1	Endocare : Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference	PR
30/11/-1	Endocare : Endocare Reports 2007 Annual and Fourth Quarter Financial Results	PR
30/11/-1	ENDOCARE : Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity	PR
30/11/-1	ENDOCARE : Reports 2009 First Quarter Financial Results	PR
30/11/-1	ENDOCARE : Reports 2008 Annual and Fourth Quarter Financial Results	PR
30/11/-1	ENDOCARE : to Present at 2nd Annual OneMedForum	PR
30/11/-1	ENDOCARE : 38 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Espace mes listes

Palmarès

Suite du Palmarès

Palmarès

Suite du Palmarès

Devises / Forex

Matières Premières

Cryptomonnaies

Taux d'Intérêts

-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !

PROFITEZ-EN MAINTENANT